Evaluación y Manejo del Cáncer de Pulmón de Células No Pequeñas (CPCNP) Temprano y localmente avanzado: 2do Consenso Nacional de la Sociedad Panameña de Oncología (SPO). (Mesa 4)
[Evaluación y Manejo del Cáncer de Pulmón de Células No Pequeñas (CPCNP) Temprano y localmente avanzado: 2do Consenso Nacional de la Sociedad Panameña de Oncología (SPO). (Mesa 4)]Yamilet Pereira1, I Véliz2, G Pérez-Jiménez3, R Araúz3, Y Ruíz3, M Guardia2, J Lio3, K Franco3, C Aguilar2, A Crismatt4
1. Instituto Oncológico Nacional.; 2. Instituto Oncológico Nacional; 3. Hospital Santo Tomás.
Descargas
Resumen
ResumenDespués de confirmado el diagnóstico histológico de cáncer de pulmón de células no pequeñas (CPCNP) se debe proceder a una evaluación clínica completa. En la evaluación por el grupo multidisciplinario es importante definir de manera inicial si el paciente tiene enfermedad a distancia. De no tenerla, el siguiente paso es definir la presencia de enfermedad ganglionar mediastinal y la capacidad funcional pulmonar del paciente, ya que el tratamiento a seguir dependerá de la evaluación minuciosa de dichas variables.
[Evaluation and Management of Non-small Cell Lung Cancer (NSCLC) Early and locally advanced: 2nd National Consensus of the Panamanian Oncology Society (SPO).]
Abstract
After the histological diagnosis of non-small cell lung cancer (NSCLC) has been confirmed, a complete clinical evaluation should be performed. In the evaluation by the multidisciplinary group it is important to define in an initial way if the patient has distant disease. If not, the next step is to define the presence of mediastinal lymph node disease and the pulmonary functional capacity of the patient, since the treatment to be followed will depend on the detailed evaluation of these variables.
Abstract
Resumen
Después de confirmado el diagnóstico histológico de cáncer de pulmón de células no pequeñas (CPCNP) se debe proceder a una evaluación clínica completa. En la evaluación por el grupo multidisciplinario es importante definir de manera inicial si el paciente tiene enfermedad a distancia. De no tenerla, el siguiente paso es definir la presencia de enfermedad ganglionar mediastinal y la capacidad funcional pulmonar del paciente, ya que el tratamiento a seguir dependerá de la evaluación minuciosa de dichas variables.
[Evaluation and Management of Non-small Cell Lung Cancer (NSCLC) Early and locally advanced: 2nd National Consensus of the Panamanian Oncology Society (SPO).]
Abstract
After the histological diagnosis of non-small cell lung cancer (NSCLC) has been confirmed, a complete clinical evaluation should be performed. In the evaluation by the multidisciplinary group it is important to define in an initial way if the patient has distant disease. If not, the next step is to define the presence of mediastinal lymph node disease and the pulmonary functional capacity of the patient, since the treatment to be followed will depend on the detailed evaluation of these variables.
Citas
[1] Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for Staging Non-small Cell Lung Cancer: Diagnosis and management of lung cancer, 3rd ed.: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143 Suppl: e211S-50S.
[2] Pinilla I, Gómez León N. The usefulness of PET/CT in lung cancer. Radiología. 2009; 51: 248-60.
[3] De Leyn P, Dooms C, Kuzdzal J, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small cell lung cancer. Eur J Cardiothorac Surg. 2014; 45:787-98.
[4] Alonso Moralejo R, Sayas Catalán J, García Luján R, et al. Utilidad de la tomografía por emisión de positrones en la detección de metástasis ocultas extra torácicas en el carcinoma broncogénico no células pequeñas. Arch Bronconeumol. 2010; 46: 238-43.
[5] Paul NS, Ley S, Metser U. Optimal imaging protocols for lung cancer staging: CT, PET, MR imaging, and the role of imaging. Radiol Clin North Am. 2012; 50: 935-49.
[6] Terán MD, Brock MV. Staging lymph node metastases from lung cancer in the mediastinum. J Thorac Dis. 2014; 6:230-6.
[7] Lee PC, Port JL, Korst RJ, Liss Y, Meherally DN, Altorki NK. Risk factors for occult mediastinal metastases in clinical stage I non-small cell lung cancer. Ann Thorac Surg. 2007; 84:177-81.
[8] Yasufuku K, Nakajima T, Motoori K, Sekine Y, Shibuya K, Hiroshima K, et al. Comparison of endobronchial ultrasound, positron emission tomography, and CT for lymph node staging of lung cancer. Chest. 2006; 130: 710-8.
[9] Felipe Villar Álvareza, Ignacio Muguruza, José Belda Sanchis, et al. Recomendaciones SEPAR de diagnóstico y tratamiento del cáncer de pulmón de células no pequeñas. Arch Bronconeumol. 2016; 52 (Supl 1):2-62.
[10] Fleisher LA, Beckman JA, Brown KA, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines. ACC/AHA 2007 Guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2007; 50: e159-241.
[11] Brunelli A, Varela G, Salati M, et al. Recalibration of the revised cardiac risk index in lung resection candidates. Ann Thorac Surg. 2010; 90:199-203.
[12] Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation. 1999; 100: 1043-9.
[13] Brunelli A, Kim AW, Berger KI, et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence- based clinical practice guidelines. Chest. 2013; 143 Suppl: e166S-90S.
[14] Brunelli A, Charloux A, Bolliger CT et al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J 2009; 34: 17–41.
[15] Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995; 60: 615–622.
[16] Rami-Porta R, Tsuboi M. Sublobar resection for lung cancer. Eur Respir J 2009; 33: 426–435.
[17] Yan TD, Black D, Bannon PG et al. Systematic review and meta-analysis of randomized trials on safety and efficacy of video-assisted thoracic surgery lobectomy for early-stage non-small cell lung cancer. J Clin Oncol 2009; 27: 2553–2562.
[18] Villamizar NR, Darraibe MD, Burfeind WR et al. Thoracoscopic lobectomy is associated with lower morbidity compared with thoracotomy. J Thorac Cardiovasc Surg 2009; 138: 419–425.
[19] Flores RM, Park BJ, Dycoco J et al. Lobectomy by video-assisted thoracic surgery (VATS) versus thoracotomy for lung cancer. J Thorac Cardiovasc Surg 2009; 138: 11–18.
[20] Peterson RP, Pham D, Burfeind WR et al. Thoracoscopic lobectomy facilitates the delivery of chemotherapy arte resection for lung cancer. Ann Thorac Surg 2007; 83: 1245–1249.
[21] Quiao X, Tullgren O, Lax I et al. The role of radiotherapy in treatment of stage I non-small-cell lung cancer. Lung Cancer 2003; 41: 1–11.
[22] Onishi H, Araki T, Shirato H et al. Stereotactic hypofractionated high dose irradiation for stage I NSCLC: clinical outcomes in 245 pts in a Japanese multiinstitutional study. Cancer 2004; 101: 1623–1631.
[23] Wu YI, Huang ZF, Wang SY et al. A randomized trial of systematic nodal dissection in resectable non-small cell lung cancer. Lung Cancer 2002; 36: 1–6.
[24] Darling GE, Allen MS, Decker PA et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg 2011; 141: 662–670.
[25] NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Non-small cell lung cancer, version 3.2017. Available at https: //www.nccn.org/professionals/physician_gls/pdf/nscl.pdf, Accessed Jan 14, 2017.
[26] Strauss GM, Herndon JE, 2nd, Maddaus MA et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008; 26: 5043–5051.
[27] Winton T, Livingston R, Johnson D et al. Vinorelbine plus cisplatin vs. Observation in resected non-small cell lung cancer. N Engl J Med 2005; 352: 2589–2597.
[28] Pepe C, Hasan B, Winton TL et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol 2007; 25: 1553–1561. Lim E, Harris G, Patel A et al.
[29] Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials. J Thorac Oncol 2009; 4:1380–1388.
[30] Felip E, Rosell R, Maestre JA et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small cell lung cancer. J Clin Oncol 2010; 28: 3138–3145.
[31] Gilligan D, Nicolson M, Smith I et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet 2007; 369: 1929–1937.
[32] Kelly K, Altorki NK, Eberhardt WE, O'Brien ME, Spigel DR, Crinò L, Tsai CM, Kim JH, Cho EK, Hoffman PC, Orlov SV. Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non–small-cell lung cancer (RADIANT): A randomized, double-blind, phase III trial. Journal of Clinical Oncology. 2015 Aug 31; 33[34]:4007-14.
[33] Arriagada R, Auperin A, Burdett S et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two metaanalyses of individual patient data. Lancet 2010; 375: 1267–1277.
[34] Pignon JP, Stewart LA. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb non-small cell lung cancer: a meta-analysis. Cancer 1996; 77: 2413–2414
[35] Palma DA, Senan S, Tsujino K et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 2013; 85: 444–450.
[36] Vokes EE, Herndon JE, Kelley MJ et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007; 25: 1698–1704.
[37] Hanna N, Neubauer M, Yiannoutsos C et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small cell lung cancer: The Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008; 26: 5755–5760.
[38] Jalal SI, Riggs HD, Melnyk A et al. Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology. Ann Oncol 2012; 23: 1730–1738.
[39] Kelly K, Chansky K, Gaspar LE et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small cell lung cancer: SWOG S0023. J Clin Oncol 2008; 26: 2450–2456.
[40] Vansteenkiste J, Van Damme V, Dooms C. Generalized or personalized treatment for stage IIIA-N2 non-small cell lung cancer? Expert Opin Pharmacother 2010; 11:1605–1609.
[41] Albain KS, Swann RS, Rusch VW et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small cell lung cancer: a phase III randomised controlled trial. Lancet 2009; 374: 379–386.
[42] Van Meerbeeck JP, Kramer GW, Van Schil PE et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non small cell lung cancer. J Natl Cancer Inst 2007; 99: 442–450.
[43] Auperin A, Le Péchoux C, Rolland E et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small cell lung cancer. J Clin Oncol 2010; 28: 2181–2190.
[44] Atagi S, Kawahara M, Yokoyama A et al. Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol 2012; 13: 671–678.
Licencia
Derechos autoriales y de reproducibilidad. La Revista Médica de Panama es un ente académico, sin fines de lucro, que forma parte de la Academia Panameña de Medicina y Cirugía. Sus publicaciones son de tipo acceso gratuito de su contenido para uso individual y académico, sin restricción. Los derechos autoriales de cada artículo son retenidos por sus autores. Al Publicar en la Revista, el autor otorga Licencia permanente, exclusiva, e irrevocable a la Sociedad para la edición del manuscrito, y otorga a la empresa editorial, Infomedic International Licencia de uso de distribución, indexación y comercial exclusiva, permanente e irrevocable de su contenido y para la generación de productos y servicios derivados del mismo. En caso que el autor obtenga la licencia CC BY, el artículo y sus derivados son de libre acceso y distribución.
